Pharmacology of exenatide (synthetic exendin-4): A potential therapeutic for improved glycemic control of type 2 diabetes

Regulatory Peptides

Volumn 117, Issue 2, 2004, Pages 77-88

  Nielsen, Loretta L ^a   Young, Andrew A ^a   Parkes, David G ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Exenatide; Pharmacology; Type 2 diabetes

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; UNCLASSIFIED DRUG;

APOPTOSIS; CELL PROLIFERATION; CELL STIMULATION; DISEASE COURSE; FOOD INTAKE; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HALF LIFE TIME; HUMAN; IN VIVO STUDY; INSULIN RELEASE; MEDICAL RESEARCH; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STOMACH EMPTYING;

EID: 0347360186     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2003.10.028     Document Type: Review

References (75)

1. Eng J., Kleinman W.A., Singh L., Singh G., Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue from Heloderma suspectum venom. J. Biol. Chem. 267:1992;7402-7405.
2. Young A.A. Glucagon-like peptide-1, exendin and insulin sensitivity. Hansen B., Shafrir E. Insulin Resistance and Insulin Resistance Syndrome. 2002;235-262 Harwood Academic, New York.
3. Drucker D.J. Glucagon-like peptides. Diabetes. 47:1998;159-169.
4. Chen Y.E., Drucker D. Tissue-specific expression of unique mRNAs that encode pro-glucagon-derived peptides or exendin-4 in the lizard. J. Biol. Chem. 272:1997;4108-4115.
5. Kieffer T.J., McIntosh C.H., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 136:1995;3585-3596.
6. Deacon C.F., Nauck M.A., Toft-Nielsen M., Pridal L., Willms B., Holst J.J. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 44:1995;1126-1131.
7. Göke R., Fehmann H.C., Linn T., Schmidt H., Krause M., Eng J.et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J. Biol. Chem. 268:1993;19650-19655.
8. Egan J.M., Clocquet A.R., Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J. Clin. Endocrinol. Metab. 87:2002;1282-1290.
9. Parkes D.G., Pittner R., Jodka C., Smith P., Young A. Insulinotropic actions of exendin-4 and glucagon- like peptide-1 in vivo and in vitro. Metabolism. 50:2001;583-589.
10. Kolterman O.G., Buse J.B., Fineman M.S., Gaines E., Heintz S., Bicsak T.A.et al. Synthetic exendin-4 (AC2993) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 88:2003;3082-3089.
11. Young A.A., Gedulin B.R., Bhavsar S., Bodkin N., Jodka C., Hansen B.et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes. 48:1999;1026-1034.
12. Parkes D., Gedulin S., Smith P., Young A. Effect of exendin-4 on glucagon secretion in lean and obese Zucker (ZDF) rats. Diabetes. 50(Suppl. 2):2001;A313.
13. Jodka C., Gedulin B., Young A. Exendin-4 potently regulates gastric emptying in rats. Diabetes. 47:1998;403A. [Abs].
14. Rayner C.K., Samsom M., Jones K.L., Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care. 24:2001;371-381.
15. Bhavsar S., Watkins J., Young A. Comparison of central and peripheral effects of exendin-4 and GLP- 1 on food intake in rats. Program and Abstracts: 80th Annual Meeting of the Endocrine Society. 1998;433. [Abs].
16. Szayna M., Doyle M.E., Betkey J.A., Holloway H.W., Spencer R.G.S., Greig N.H.et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology. 141:2000;1936-1941.
17. Xu G., Stoffers D.A., Habener J.F., Bonner-Weir S. Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 48:1999;2270-2276.
18. Tourrel C., Bailbé D., Meile M.-J., Kergoat M., Portha B. Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes. 50:2001;1562-1570.
19. Tourrel C., Bailbé D., Lacorne M., Meile M.J., Kergoat M., Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes. 51:2002;1443-1452.
20. Greig N.H., Holloway H.W., De Ore K.A., Jani D., Wang Y., Zhou J.et al. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia. 42:1999;45-50.
21. Parkes D., Jodka C., Smith P., Nayak S., Rinehart L., Gingerich R.et al. Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev. Res. 53:2001;260-267.
22. Postprandial blood glucose. Diabetes Care. 24:2001;775-778.
23. Kahn S.E., Porte D. Jr. Pathophysiology of type II diabetes mellitus. Porte D. Jr., Sherwin R.S. Diabetes Mellitus. 5th ed. 1997;487-512 Appleton & Lange, Stamford, CT.
24. Weyer C., Bogardus C., Mott D.M., Pratley R.E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J. Clin. Invest. 104:1999;787-794.
25. Harris M.I., Flegal K.M., Eastman R.C., Eberhardt M.S., Cowie C.C. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care. 22:1999;403-408.
26. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 44:1995;1249-1258.
27. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in subjects with type 2 diabetes. Lancet. 352:1998;837-853.
28. Thorens B. Expression cloning of the pancreatic β-cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc. Natl. Acad. Sci. U. S. A. 89:1992;8641-8645.
29. Raufman J.P., Singh L., Singh G., Eng J. Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4. J. Biol. Chem. 267:1992;21432-21437.
30. Raufman J.P., Singh L., Eng J. Exendin-3, a novel peptide from Heloderma horridum venom, interacts with vasoactive intestinal peptide receptors and a newly described receptor on dispersed acini from guinea pig pancreas. Description of exendin-3(9-39), a specific exendin receptor antagonist. J. Biol. Chem. 266:1991;2897-2902.
31. Brubaker P.L., Drucker D.J. Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels. 8:2002;179-188.
32. Raufman J.P. Bioactive peptides from lizard venoms. Regul. Pept. 61:1996;1-18.
33. Fehmann H.C., Bode H.P., Ebert T., Karl A., Goke B. Interaction of GLP-1 and leptin at rat pancreatic β-cells: effects on insulin secretion and signal transduction. Horm. Metab. Res. 29:1997;572-576.
34. Thorens B., Porret A., Bühler L., Deng S.P., Morel P., Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Diabetes. 42:1993;1678-1682.
35. Baggio L., Adatia F., Bock T., Brubaker P.L., Drucker D.J. Sustained expression of exendin-4 does not perturb glucose homeostasis, β-cell mass, or food intake in metallothionein-preproexendin transgenic mice. J. Biol. Chem. 275:2000;34471-34477.
36. Scrocchi L.A., Marshall B.A., Cook S.M., Brubaker P.L., Drucker D.J. Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling. Diabetes. 47:1998;632-639.
37. Edwards C.M., Todd J.F., Mahmoudi M., Wang Z., Wang R.M., Ghatei M.et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes. 48:1999;86-93.
38. Burcelin R., Da Costa A., Drucker D., Thorens B. Glucose competence of the heptoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes. 50:2001;1720-1728.
39. Scrocchi L.A., Brown T.J., MacLusky N., Brubaker P.L., Auerbach A.B., Joyner A.L.et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene. Nat. Med. 2:1996;1254-1258.
40. MacLusky N., Cook S., Scrocchi L., Shin J., Kim J., Vaccarino F.et al. Neuroendocrine function in mice with complete disruption of GLP-1 receptor signaling. Endocrinology. 141:2000;752-762.
41. Pederson R.A., Satkunarajah M., McIntosh C.H., Scrocchi L.A., Flamez D., Schuit F.et al. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor-/- mice. Diabetes. 47:1998;1046-1052.
42. Nishizawa M., Nakabayashi H., Kawai K., Ito T., Kawakami S., Nakagawa A.et al. The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor. J. Auton. Nerv. Syst. 80:2000;14-21.
43. Idris I., Patiag D., Gray S., Donelly R. Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1. Biochem. Pharmacol. 63:2002;993-996.
44. Holst J.J. Therapy of type 2 diabetes mellitus based on the action of glucagon-like peptide-1. Diabetes Metab. Res. Rev. 18:2002;430-441.
45. Ribel U., Larsen M.O., Rolin B., Carr R.D., Wilken M., Sturis J.et al. NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. Eur. J. Pharmacol. 451:2002;217-225.
46. Zander M., Madsbad S., Madsen J.L., Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet. 359:2002;824-830.
47. Nielsen L.L., Baron A.D. Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. Curr. Opin. Invest. Drugs. 4:2003;401-405.
48. Fineman M.S., Bicsak T.A., Shen L.Z., Taylor K., Gaines E., Varns A.et al. Effect on glycemic control of synthetic exendin-4 (AC2993) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Physiol. Behav., Diabetes Care. 26:2003;2370-2377.
49. Egan J.M., Meneilly G.S., Elahi D. Effects of one month bolus subcutaneous administration of exendin-4 in type 2 diabetes. Am. J. Physiol., Endocrinol. Metab. 284:2003;E1072-E1079.
50. Henquin J.-C. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes. 49:2000;1751-1760.
51. Siegel E.G., Schulze A., Schmidt W.E., Creutzfeldt W. Comparison of the effect of GIP and GLP-1(7-36 amide) on insulin release from rat pancreatic islets. Eur. J. Clin. Invest. 22:1992;154-157.
52. Zawalich W.S., Zawalich K.C., Rasmussen H. Influence of glucagon-like peptide-1 on beta cell responsiveness. Regul. Pept. 44:1993;277-283.
53. Heller R.S., Apnte G.W. Intra-islet regulation of hormone secretion by glucagon-like peptide-1(7-36)amide. Am. J. Physiol. 32:1995;G852-G860.
54. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.L. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:1985;412-419.
55. Reaven G.M., Chen Y.D., Golay A., Swislocki A.L., Jaspan J.B. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 64:1987;106-110.
56. Baron A.D., Schaeffer L., Shragg P., Kolterman O.G. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes. 36:1987;274-283.
57. Mahler R.J., Adler M.L. Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment. J. Clin. Endocrinol. Metab. 84:1999;1165-1171.
58. Moore M.C., Cherrington A.D. Regulation of net hepatic glucose uptake: interaction of neural and pancreatic mechanisms. Reprod. Nutr. Dev. 36:1996;399-406.
59. Soria B. In-vitro differentiation of pancreatic β-cells. Differentiation. 68:2001;205-219.
60. Abraham E.J., Leech C.A., Lin J.C., Zulewski H., Habener J.F. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology. 143:2002;3152-3161.
61. Zhou J., Wang X., Pineyro M.A., Egan J.M. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes. 48:1999;2358-2366.
62. Stoffers D.A., Kieffer T.J., Hussain M.A., Drucker D.J., Bonner-Weir S., Habener J.F.et al. Insulinotrophic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in the mouse pancreas. Diabetes. 49:2000;741-748.
63. Li Y., Hansotia T., Yusta B., Ris F., Halban P.A., Drucker D.J. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem. 278:2003;471-478.
64. Rolin B., Larsen M.O., Gotfredsen C.F., Deacon C.F., Carr R.D., Wilken M.et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increase beta-cell mass in diabetic mice. Am. J. Physiol., Endocrinol. Metab. 283:2002;E745-E752.
65. Wang Q., Brubaker P.L. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia. 45:2002;1263-1273.
66. Stoffers D.A., Desai B.M., DeLeon D.D., Simmons R.A. Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. Diabetes. 52:2003;734-740.
67. De León D.D., Deng S., Madani R., Ahima R.S., Drucker D.J., Stoffers D.A. Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes. 52:2003;365-371.
68. Dupre J., Behme M.T., Hramiak I.M., McDonald T.J. Subcutaneous glucagon-like peptide-1 combined with insulin normalized postcibal glycemic excursions in IDDM. Diabetes Care. 20:1997;381-384.
69. Nauck M.A., Niedereich-Holz U., Ettler R., Holst J.J., Orskov C., Ritzel R.et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol. 273:1997;E981-E988.
70. Green G.M., Guan D., Schwartz J.G., Phillips W.T. Accelerated gastric emptying of glucose in Zucker type 2 diabetic rats: role in postprandial hyperglycaemia. Diabetologia. 40:1997;136-142.
71. Harju E. Nordback I: postprandial hyperglycemia after different carbohydrates in patients with total gastrectomy. Surg. Gynecol. Obstet. 165:1987;41-45.
72. Moyses C., Young A., Kolterman O. Modulation of gastric emptying as a therapeutic approach to glycaemic control. Diabetic Med. 13:1996;S34-S38.
73. Edwards C.M., Stanley S.A., Davis R., Brynes A.E., Frost G.S., Seal L.J.et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am. J. Physiol., Endocrinol. Metab. 281:2001;E155-E161.
74. Nishizawa M., Moore M.C., Shiota M., Gustavson S.M., Snead W.L., Neal D.W.et al. Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs. Am. J. Physiol., Endocrinol. Metab. 284:2003;E1027-E1036.
75. Vella A., Shah P., Reed A.S., Adkins A.S., Basu R., Rizza R.A. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia. 45:2002;1410-1415.